SONIA MORETTI, FLAVIA MANCINI, ALESSANDRA BORSETTI*
BIOCELL, Vol.46, No.12, pp. 2695-2699, 2022, DOI:10.32604/biocell.2022.022257
- 10 August 2022
Abstract Direct-acting antiviral (DAA) therapies are efficacious for the achievement of sustained virologic response (SVR) in almost all treated hepatitis C virus (HCV)-infected patients. However, the impacts of HCV eradication on immune function and chronic immune activation in the long-term remain controversial and limited, especially in patients co-infected with human immunodeficiency virus (HIV). Indeed, although restoration of many immune responses clearly can be observed, several features of immune perturbations persist over time after HCV clearance. Understanding the degree and reasons of the partial recovery of the immune system in chronic HCV/HIV co-infection after HCV elimination is More >
Login
Register
